CA2866435A1 - Use of thymosin alpha for the treatment of sepsis - Google Patents

Use of thymosin alpha for the treatment of sepsis Download PDF

Info

Publication number
CA2866435A1
CA2866435A1 CA2866435A CA2866435A CA2866435A1 CA 2866435 A1 CA2866435 A1 CA 2866435A1 CA 2866435 A CA2866435 A CA 2866435A CA 2866435 A CA2866435 A CA 2866435A CA 2866435 A1 CA2866435 A1 CA 2866435A1
Authority
CA
Canada
Prior art keywords
sepsis
administered
days
thymosin peptide
alpha thymosin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA2866435A
Other languages
English (en)
French (fr)
Inventor
Xiangdong GUAN
Jianfeng Wu
Cynthia Tuthill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Affiliated Hospital of Sun Yat Sen University
Sciclone Pharmaceuticals International Pte Ltd
Original Assignee
First Affiliated Hospital of Sun Yat Sen University
Sciclone Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Affiliated Hospital of Sun Yat Sen University, Sciclone Pharmaceuticals LLC filed Critical First Affiliated Hospital of Sun Yat Sen University
Publication of CA2866435A1 publication Critical patent/CA2866435A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2292—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CA2866435A 2012-03-30 2013-03-28 Use of thymosin alpha for the treatment of sepsis Pending CA2866435A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201261618563P 2012-03-30 2012-03-30
US61/618,563 2012-03-30
US201261643824P 2012-05-07 2012-05-07
US61/643,824 2012-05-07
US13/835,107 2013-03-15
US13/835,107 US20130296223A1 (en) 2012-03-30 2013-03-15 Use of thymosin alpha for the treatment of sepsis
PCT/US2013/034394 WO2013149030A2 (en) 2012-03-30 2013-03-28 Use of thymosin alpha for the treatment of sepsis

Publications (1)

Publication Number Publication Date
CA2866435A1 true CA2866435A1 (en) 2013-10-03

Family

ID=49261395

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2866435A Pending CA2866435A1 (en) 2012-03-30 2013-03-28 Use of thymosin alpha for the treatment of sepsis

Country Status (8)

Country Link
US (5) US20130296223A1 (https=)
EP (2) EP3741386A1 (https=)
JP (6) JP2015514093A (https=)
KR (1) KR20150048663A (https=)
CN (2) CN105338996A (https=)
CA (1) CA2866435A1 (https=)
HK (1) HK1246694A1 (https=)
WO (1) WO2013149030A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20180017559A1 (en) * 2014-08-12 2018-01-18 Arsanis Biosciences Gmbh Predicting s. aureus disease
WO2019028448A1 (en) * 2017-08-04 2019-02-07 The Johns Hopkins University APPLICATION FOR EARLY PREDICTION OF SEPTIC SHOCK WAITING
US11504071B2 (en) * 2018-04-10 2022-11-22 Hill-Rom Services, Inc. Patient risk assessment based on data from multiple sources in a healthcare facility
CN111971068B (zh) * 2018-04-20 2025-09-02 康柏辛股份有限公司 败血症和败血性休克的治疗
EP4370129A1 (en) 2021-07-12 2024-05-22 2N Pharma ApS Carnitine-palmitoyl-transferase-1 (cpt-1) inhibitors for use in a method of preventing or treating sepsis in a mammalian subject

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4079127A (en) 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
TW252045B (https=) * 1993-10-07 1995-07-21 Allan L Goldstein
AU7964194A (en) 1993-10-07 1995-05-01 George Washington University Medical Center, The Method of treating septic shock using thymosin-alpha1
US5972933A (en) * 1998-01-08 1999-10-26 Ed. Geistlich Sohne Ag Fur Chemische Industrie Method of treating microbial infections
UA80957C2 (en) 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
US7897567B2 (en) * 2002-11-25 2011-03-01 Sciclone Pharmaceuticals, Inc. Methods of protecting against radiation damage using alpha thymosin
WO2007041156A2 (en) * 2005-09-29 2007-04-12 Nektar Therapeutics Antibiotic formulations, unit doses, kits, and methods
CN101020048A (zh) * 2007-02-12 2007-08-22 广东天普生化医药股份有限公司 一种用于治疗脓毒症的药物组合物
CA2679626C (en) * 2007-03-21 2012-10-23 Bausch & Lomb Incorporated Fluoroquinolones for treating, reducing, ameliorating, or preventing infections caused by antibacterial-drug resistant bacteria
WO2009075813A1 (en) * 2007-12-12 2009-06-18 Sciclone Pharmaceuticals, Inc. Treatment of melanoma with alpha thymosin peptides in combination with antibodies against cytotoxic t lymphocyte-associated antigen 4 (ctla4)
CN101514228A (zh) * 2008-02-21 2009-08-26 张卓兵 N-端修饰的人胸腺肽α1复合物及其制备方法
WO2010129947A2 (en) * 2009-05-08 2010-11-11 Sciclone Pharmaceuticals, Inc. Alpha thymosin peptides as vaccine enhancers
US20130225477A1 (en) * 2010-02-25 2013-08-29 Agennix Ag Oral Lactoferrin in the Treatment of Severe Sepsis
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection

Also Published As

Publication number Publication date
JP2015514093A (ja) 2015-05-18
JP2021100983A (ja) 2021-07-08
US20180236036A1 (en) 2018-08-23
EP2841088A2 (en) 2015-03-04
EP2841088B1 (en) 2020-06-17
CN107519483A (zh) 2017-12-29
CN105338996A (zh) 2016-02-17
US20130296223A1 (en) 2013-11-07
JP2025107346A (ja) 2025-07-17
HK1207314A1 (en) 2016-01-29
JP2019156854A (ja) 2019-09-19
KR20150048663A (ko) 2015-05-07
JP2017214377A (ja) 2017-12-07
WO2013149030A2 (en) 2013-10-03
JP2022176345A (ja) 2022-11-25
EP2841088A4 (en) 2015-10-14
HK1246694A1 (zh) 2018-09-14
US20210106656A1 (en) 2021-04-15
US20150024994A1 (en) 2015-01-22
EP3741386A1 (en) 2020-11-25
US20240091314A1 (en) 2024-03-21

Similar Documents

Publication Publication Date Title
US20240091314A1 (en) Use of thymosin alpha for the treatment of sepsis
Wu et al. The efficacy of thymosin alpha 1 for severe sepsis (ETASS): a multicenter, single-blind, randomized and controlled trial
ES2271468T3 (es) Nuevas indicaciones de la lecitina de union a manano (mbl) en el tratamiento de individuos inmunocomprometidos.
Schüller et al. Immunomodulation to prevent or treat neonatal sepsis: past, present, and future
Eyerich et al. Chronic mucocutaneous candidiasis, from bench to bedside
JP6713148B2 (ja) 腹膜炎の治療のための組成物
HK40035899A (en) Use of thymosin alpha for the treatment of sepsis
HK1207314B (en) Use of thymosin alpha for the treatment of sepsis
CN103648515B (zh) 作为辐射缓和剂和辐射防护剂的bpi和其同源物
EP4138881A1 (en) Composition comprising a dna-degrading enzyme for use in a method for the treatment of immunosuppression after acute tissue injury
JP6373963B2 (ja) 移植のためのｈ因子
Mylonas et al. Type I interferons link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea
JP6484215B2 (ja) 関節リウマチの治療のためのｈ因子
RU2273494C2 (ru) Новые показания к применению маннан-связывающего лектина при лечении иммунокомпромисных индивидуумов
Hovnanian Type I interferons link skin-associated dysbiotic commensal bacteria to pathogenic inflammation and angiogenesis in rosacea
CN104800829A (zh) 寡肽联合或与吗啡的组合在制备用于镇痛的药物中的用途
US20150031617A1 (en) Use of thymosin alpha for treatment of purulent rhinosinusitis

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180327

FZDE Discontinued

Effective date: 20220809

FZDC Discontinued application reinstated

Effective date: 20230111

FZDC Discontinued application reinstated

Effective date: 20230111

FZDC Discontinued application reinstated

Effective date: 20230111

FZDC Discontinued application reinstated

Effective date: 20230111

FZDC Discontinued application reinstated

Effective date: 20230111

FZDC Discontinued application reinstated

Effective date: 20230111

FZDC Discontinued application reinstated

Effective date: 20230111

C11 Application revival requested

Free format text: ST27 STATUS EVENT CODE: N-6-6-C10-C11-C106 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REINSTATEMENT REQUEST RECEIVED

Effective date: 20241204

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: N-6-6-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250204

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 12TH ANNIV.) - STANDARD

Year of fee payment: 12

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250321

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: N-6-6-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250321